On Jul. 22, 2008, Bentley Pharmaceuticals was acquired by Teva Pharmaceutical Industries. At closing, Bentley consisted solely of its generic pharmaceutical operations, following the spin-off of its drug delivery business to its stockholders on Jun. 30, 2008.

The aggregate purchase price paid by Teva was approximately $360 million in cash, or approximately $14.82 per Bentley share.